axicabtagene ciloleucel
Selected indexed studies
- Axicabtagene Ciloleucel. (, 2006) [PMID:40460225]
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. (N Engl J Med, 2022) [PMID:34891224]
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. (Lancet Oncol, 2019) [PMID:30518502]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. (2019) pubmed
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. (2022) pubmed
- Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. (2023) pubmed
- Axicabtagene Ciloleucel. (2006) pubmed
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. (2022) pubmed
- Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. (2023) pubmed
- Axicabtagene Ciloleucel for Large B-Cell Lymphoma. (2011) pubmed
- Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. (2024) pubmed
- Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). (2024) pubmed
- PMID:40138508 (2023) pubmed